Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q1 2023 · 10-Q
Revenue$0.00$0.00no prior Q1 2022 on file Net Income-$18.13M-$18.13MN/M vs Q1 2022 EPS Diluted-$2.05-$2.05N/M vs Q1 2022 Operating Income-$7,636,000— Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Free Cash Flowderived-$16,438,000N/M ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end